1007306-65-1

Basic information

• Product Name: (3-Hydroxy-cyclopentylmethyl)-carbamic acid tert-butyl ester
• Synonyms: (3-Hydroxy-cyclopentylmethyl)-carbamic acid tert-butyl ester
• CAS NO: 1007306-65-1
• Molecular Formula: C11H21NO3
• Molecular Weight: 215.28934
• Mol File: 1007306-65-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3-Hydroxy-cyclopentylmethyl)-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (3-Hydroxy-cyclopentylmethyl)-carbamic acid tert-butyl ester(1007306-65-1)
• EPA Substance Registry System: (3-Hydroxy-cyclopentylmethyl)-carbamic acid tert-butyl ester(1007306-65-1)

Safety Data

• Hazardous Substances Data: 1007306-65-1(Hazardous Substances Data)

Upstream product

• 81266-47-9 (+/-)-3-(nitromethyl)cyclopentanone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 116649-87-7 3-(aminomethyl)cyclopentanol 
• 542-92-7 cyclopenta-1,3-diene 
• 1007306-62-8 (1S,3 S) 3-aminomethylcyclopentanol 
• 4492-42-6 (cyclopent-3-ene)methylamine 
• 5732-97-8 2-oxa-bicyclo[2.2.1]heptan-3-one 
• 1110772-09-2 cis-3-(aminomethyl)cyclopentan-1-ol 
• 207729-05-3 tert-butyl cyclopent-3-enylmethylcarbamate 

Relevant articles and documents

On the possibility of carbamate-directed hydroboration. An approach to the asymmetric synthesis of 1-aminocyclopentane-1,3-dicarboxylic acid

Hydroboration (using BH3) of 1-substituted 3-cyclopentenes 3, 9 and 17 and an enantioselective synthesis of the excitatory amino acid 1- aminocyclopentane-1,3-dicarboxylic acid via asymmetric hydroboration [90% de, 45% ee using (+)-IpcBH2] of cyclopentene 17 are described.

POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

6-SUBSTITUTED ISOQUINOLINE DERIVATIVES

The present invention relates to 6-substituted isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 0 or 1; o is 0 or 1; R1 is H, when Y is NH2; or R1 is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R4 is H or (C1-6)alkyl, optionally substituted with halogen, (C3-7)cycloalkyl, (C6-10)aryl or a saturated 5- or 6-membered heterocyclic ring comprising 1-3 heteroatoms independently selected from O, S and N, the (C6-10)aryl and heterocyclic ring being optionally substituted with (C1-4)alkyl, (C1-4)alkyloxy or halogen; R5 is H or (C1-4)alkyl; or a pharmaceutically acceptable salt thereof, with the proviso that the compounds of Formula I wherein X is O, Y is OH , n is 0 and m+o=2 are excluded, to pharmaceutical compositions comprising the same, as well as to the use of said 6-substituted isoquinoline derivatives for the preparation of a medicament for the treatment of ROCK-I related disorders such as glaucoma, hypertension and atherosclerosis.